Upon evaluating the therapy being administered, it was found that fatal outcomes occurred in 82.8% of ICI-associated myocarditis cases against the background of monotherapy with drugs from the anti-PD-1 group (primarily pembrolizumab (32.8%) and nivolumab (26.6%)). This evidence concerns the gene PDCD1 and myocarditis.